Clinical trial NCT00077129 (phase 2, status: completed)
Conditions: kidney cancer
ICD codes: D17.71, D30.00, D30.01, D30.02, D41.00, D41.01, D41.02
Drugs: carboplatin, paclitaxel
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed collecting duct renal cell carcinoma

               -  Advanced locally recurrent or metastatic disease

               -  Not amenable to resection

          -  Measurable disease

          -  No active CNS metastases

               -  Patients with CNS metastases previously treated with surgical resection and/or
                  radiotherapy are eligible provided there is no evidence of disease progression by
                  head CT scan or MRI at 3 months after the completion of definitive therapy

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  WBC ≥ 3,000/mm^3

          -  Absolute granulocyte count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST and ALT ≤ 2.5 times ULN

        Renal

          -  Creatinine ≤ 2 times ULN

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No peripheral neuropathy greater than grade 1

          -  No other prior malignancy except for curatively treated cancer from which the patient
             has been disease-free for the length of time considered appropriate for cure of the
             specific cancer

          -  No known hypersensitivity to Cremophor EL

          -  No active serious infection

          -  No other serious underlying medical condition that would preclude study therapy

          -  No dementia or significantly altered mental status that would preclude giving informed
             consent

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No more than 2 prior biologic response modifier (BRM) regimens

               -  Regimens may have included interleukin-2 and/or interferon alfa

          -  At least 4 weeks since prior BRM therapy

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Concurrent corticosteroids allowed

        Radiotherapy

          -  See Disease Characteristics

          -  Prior radiotherapy allowed provided there is measurable disease that has not been
             irradiated OR there is clear evidence of tumor progression in an irradiated site

          -  At least 4 weeks since prior radiotherapy

          -  No concurrent external beam radiotherapy

        Surgery

          -  See Disease Characteristics

          -  No concurrent major surgery

        Other

          -  No other concurrent anticancer drugs